These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15449183)

  • 1. A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
    Markman M; Belinson J
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):26-30. PubMed ID: 15449183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Matsumoto K; Shibata T; Sato A; Fukuda H; Konishi I; Kamura T; Yoshikawa H;
    Jpn J Clin Oncol; 2008 Jan; 38(1):74-7. PubMed ID: 18258715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
    Guardiola E; Delroeux D; Heyd B; Combe M; Lorgis V; Demarchi M; Stein U; Royer B; Chauffert B; Pivot X
    World J Surg Oncol; 2009 Feb; 7():14. PubMed ID: 19203351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary.
    Balat O
    Eur J Gynaecol Oncol; 2004; 25(2):195-6. PubMed ID: 15032280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
    Muñoz-Casares FC; Rufián S; Arjona-Sánchez Á; Rubio MJ; Díaz R; Casado Á; Naranjo Á; Díaz-Iglesias CJ; Ortega R; Muñoz-Villanueva MC; Muntané J; Aranda E
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):267-74. PubMed ID: 21499894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
    Onda T; Kobayashi H; Nakanishi T; Hatae M; Iwasaka T; Konishi I; Shibata T; Fukuda H; Kamura T; Yoshikawa H
    Gynecol Oncol; 2009 Apr; 113(1):57-62. PubMed ID: 19181369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
    Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
    Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
    Rouzier R; Gouy S; Selle F; Lambaudie E; Floquet A; Fourchotte V; Pomel C; Colombo PE; Kalbacher E; Martin-Francoise S; Fauvet R; Follana P; Lesoin A; Lecuru F; Ghazi Y; Dupin J; Chereau E; Zohar S; Cottu P; Joly F
    Eur J Cancer; 2017 Jan; 70():133-142. PubMed ID: 27914243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC.
    Medina Fernández FJ; Muñoz-Casares FC; Arjona-Sánchez A; Casado-Adam A; Gómez-Luque I; Garcilazo Arismendi DJ; Thoelecke H; Rufián Peña S; Briceño Delgado J
    Ann Surg Oncol; 2015 Apr; 22(4):1332-40. PubMed ID: 25234021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].
    Pfisterer J; Harter P; Hilpert F; du Bois A
    Chirurg; 2007 Dec; 78(12):1111-6. PubMed ID: 17994201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
    Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
    J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.